We are currently experiencing technical issues due to the Microsoft outage. This will affect delivery of multi-factor authentication emails, invoice emails and service emails. We apologise for the disruption.

Explore 3 Stock Ideas & Industry Insights Download Free Report

Definitive Healthcare Corp

Company price
1.285 USD 0.01 ( 0.39%)
Last update at 2026-11-12T15:40:00Z
VOLUME
52368
Market Cap
109.70M

Momentum Score

…

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution. The company's platform consists of various functional areas, such as sales, marketing, clinical research and product development, strategy, talent acquisition, and physician network management. It serves biopharmaceutical and medical device companies, healthcare information technology companies, and healthcare providers; and other diversified companies comprising staffing and commercial real estate firms, financial institutions, marketing and advertising agencies.Definitive Healthcare Corp. was founded in 2011 and is headquartered in Framingham, Massachusetts.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
1.28
Low
1.30
High
52 Week Price Range
0.92
Low
4.70
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Definitive Healthcare provides subscription data and analytics on healthcare providers, facilities, payers and life-sciences organizations to support commercial, clinical and research decisions. Long-term growth may be driven by rising demand for real-world data, cross-selling of expanded products, international expansion and M&A, and the company appears positioned with recurring revenue and data assets that could support durable margins.
Key risks include regulatory and data-privacy constraints, strong competition and pricing pressure, execution risk from integrating acquisitions, and sensitivity to client budget cycles and customer concentration.

Risk Score
Medium

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
1.28
Dividend Yield
-
Revenue TTM
241.52M
Revenue Per Share
2.27
Gross Profit TTM
203.57M
Debt / Equity
0.63
ROE
-40.42%
Net Debt
14.19M
ROCE
-34.21%
Diluted EPS TTM
-1.30

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -209.26M -633.75M -308.18M -39.44M -60.58M
Minority interest 60.37M 178.32M 87.35M 16.22M 10.24M
Net income -138.93M -413.12M -202.39M -22.25M -61.26M
Selling general administrative 51.63M 49.27M 58.86M 48.78M 30.53M
Selling and marketing expenses 81.64M 83.81M 94.53M 89.58M 56.39M
Gross profit 183.28M 197.47M 203.93M 180.03M 125.47M
Reconciled depreciation 56.11M 51.67M 51.44M 56.90M 59.95M
Ebit -197.97M -618.91M -292.98M -23.14M -18.69M
Ebitda -162.15M -567.24M -241.23M 33.77M 41.25M
Depreciation and amortization 35.82M 51.67M 51.75M 56.90M 59.95M
Non operating income net other - - - - -35.60M
Operating income -20.58M -710.82M -329.80M -23.14M -18.69M
Other operating expenses 262.10M 963.02M 581.22M 256.03M 184.85M
Interest expense 11.29M 14.84M 15.20M 8.41M 25.87M
Tax provision -9.96M -42.30M -36.26M -17.18M 0.68M
Interest income 6.95M 14.59M 13.64M - -
Net interest income -4.34M -0.24M -2.92M -8.41M -25.87M
Income tax expense -9.96M -42.30M -18.55M -17.18M 0.68M
Total revenue 241.52M 252.20M 251.41M 222.65M 166.15M
Total operating expenses 203.86M 908.29M 533.73M 213.40M 144.16M
Cost of revenue 58.25M 54.73M 47.48M 42.62M 40.69M
Total other income expense net -188.67M 77.08M 21.62M -16.30M -41.89M
Net income from continuing ops -199.30M -591.45M -268.45M -22.25M -61.26M
Net income applicable to common shares - - - -6.04M -51.02M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 735.49M 1089.39M 1825.90M 2120.99M 2115.99M
Intangible assets 247.48M 297.93M 323.12M 350.72M 352.47M
Other current assets 24.74M 26.78M 13.12M 12.69M 13.40M
Total liab 356.50M 482.19M 626.73M 633.77M 612.73M
Total stockholder equity 281.11M 444.38M 861.36M 952.14M 873.21M
Deferred long term liab - - - 15.20M 11.67M
Other current liab 44.77M 25.21M 51.53M 18.75M 22.66M
Common stock 0.10M 0.11M 0.12M 0.10M 0.10M
Capital stock 0.10M 0.11M 0.12M 0.10M 0.10M
Retained earnings -779.51M -640.57M -227.45M -23.71M -17.68M
Other liab - - - 235.53M 231.12M
Good will 197.22M 393.28M 1075.08M 1323.10M 1261.44M
Other assets - - - 16.45M 12.77M
Cash 163.63M 105.38M 130.98M 146.93M 387.50M
Total current liabilities 156.79M 161.16M 170.68M 132.50M 117.80M
Current deferred revenue 96.99M 93.34M 97.38M 99.69M 83.61M
Net debt 14.19M 147.73M 136.95M 128.91M -116.81M
Short term debt 11.43M 16.16M 15.99M 10.12M 6.88M
Short long term debt 8.75M 13.75M 13.75M 8.59M 6.88M
Short long term debt total 177.82M 253.11M 267.93M 275.85M 270.68M
Other stockholder equity 1061.96M 1085.44M 1086.58M 972.08M 890.72M
Property plant equipment - - - 14.14M 5.07M
Total current assets 257.61M 370.17M 380.44M 413.75M 451.56M
Long term investments - - - 0.00M 32.67M
Net tangible assets - - - -721.69M -740.71M
Short term investments 17.26M 184.79M 177.09M 184.94M -
Net receivables 51.98M 53.23M 59.25M 58.80M 43.34M
Long term debt 156.09M 229.37M 242.57M 255.76M 263.81M
Inventory - - -3.43M 10.39M 7.33M
Accounts payable 3.60M 10.76M 5.79M 3.95M 4.65M
Noncontrolling interest in consolidated entity - - - - 630.06M
Accumulated other comprehensive income -1.45M -0.61M 2.11M 3.67M 0.06M
Common stock total equity - - - - 0.10M
Retained earnings total equity - - - - -17.68M
Non currrent assets other 15.12M 16.69M 32.69M 19.28M 12.62M
Non current assets total 477.89M 719.22M 1445.46M 1707.25M 1664.43M
Capital lease obligations 7.83M 9.99M 11.61M 11.49M -
Long term debt total - - - - 263.81M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 170.59M -26.41M -154.07M -248.90M -46.73M
Change to liabilities - - - 13.05M 24.05M
Total cashflows from investing activities 153.88M -26.41M -31.78M -248.90M -46.73M
Net borrowings -77.81M -13.75M -8.59M -6.88M -199.46M
Total cash from financing activities -150.79M -56.75M -25.58M -26.70M 384.37M
Change to operating activities - - - -21.78M -18.17M
Net income -199.30M -591.45M -202.39M -22.25M -61.26M
Change in cash 58.25M -25.60M -15.96M -240.56M 362.72M
Begin period cash flow 105.38M 130.98M 146.93M 387.50M 24.77M
End period cash flow 163.63M 105.38M 130.98M 146.93M 387.50M
Total cash from operating activities 53.78M 58.20M 41.19M 35.58M 25.21M
Issuance of capital stock - - 0.00M 0.00M 834.95M
Depreciation 56.11M 51.67M 51.75M 56.90M 59.95M
Other cashflows from investing activities - -12.34M - - -40.00M
Dividends paid 3.15M 5.13M 12.28M 12.87M 8.13M
Change to inventory - - - - -3.73M
Change to account receivables 1.38M 5.69M 0.81M -13.22M -10.73M
Sale purchase of stock -49.45M -22.37M -4.43M 0.00M -231.77M
Other cashflows from financing activities -18.71M -15.50M -4.68M -6.95M 263.78M
Change to netincome - - - -2.85M 24.88M
Capital expenditures 16.72M 12.34M 2.98M 8.33M 6.73M
Change receivables - - - - -10.73M
Cash flows other operating - - - - -3.93M
Exchange rate changes - - - - -0.13M
Cash and cash equivalents changes - - - - 362.85M
Change in working capital -9.42M -25.93M -30.39M -21.95M -4.85M
Stock based compensation 29.14M 38.09M 48.74M 36.43M 9.96M
Other non cash items 188.12M 705.40M 192.19M 13.12M 20.73M
Free cash flow 37.06M 45.85M 38.21M 27.25M 18.48M

Peer Comparison*

Sector: Healthcare Industry: Health Information Services

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
DH
Definitive Healthcare Corp
0.01
0.39%
1.28 - 6.63 0.45 0.39 0.42 46.69
VEEV
Veeva Systems Inc Class A
-4.88
1.60%
299.89 43.49 29.59 12.48 5.79 10.39 33.41
PMCUF
Pro Medicus Limited
0.68
0.48%
142.50 64.90 90.91 49.11 38.05 65.12 83.47
TEM
Tempus AI, Inc. Class A Common Stock
-4.81
6.06%
74.62 - - 8.68 25.39 8.33 -
MTHRY
M3 Inc
-0.07
1.22%
5.66 31.84 26.25 0.05 4.60 0.04 0.12

Profile*

Definitive Healthcare Corp

Definitive Healthcare Corp., together with its subsidiaries, provides software as a service (SaaS) healthcare commercial intelligence platform in the United States and internationally. Its SaaS platform provides information on healthcare providers and their activities to help its customers from product development to go-to-market planning, and sales and marketing execution. The company's platform consists of various functional areas, such as sales, marketing, clinical research and product development, strategy, talent acquisition, and physician network management. It serves biopharmaceutical and medical device companies, healthcare information technology companies, and healthcare providers; and other diversified companies comprising staffing and commercial real estate firms, financial institutions, marketing and advertising agencies.Definitive Healthcare Corp. was founded in 2011 and is headquartered in Framingham, Massachusetts.

492 Old Connecticut Path, Framingham, MA, United States, 01701

508 720 4224

678

Name Title Year Born
Mr. Jason Ronald Krantz Founder & Exec. Chairman 1974
Mr. Robert W. Musslewhite J.D. CEO & Director 1970
Mr. Richard Douglas Booth Chief Financial Officer 1969
Mr. Jon Maack Pres NA
Mr. Scott Oberlink Chief Technology Officer NA
Mr. Matt Ruderman Acting Chief Legal Officer NA
Mr. Justin A. Steinman Chief Marketing Officer NA
Mr. Joseph Gianni Mirisola Chief Revenue Officer 1984
Ms. Kate Marie Shamsuddin Jensen Chief Product Officer 1986
Mr. David Kronfeld Chief Growth Officer NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…